Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carreño-Tarragona G.
- Gil-Manso R.
- Hernández-Boluda J.C.
- Martínez-Ávila J.C.
- Bellosillo B.
- Pérez-López R.
- Segura A.
- Ferrer-Marín F.
- Arellano-Rodrigo E.
- Angona A.
- García-Gutiérrez V.
- Noya M.S.
- Blanco Á.
- Zamora L.
- Navarro M.
- Senín A.
- Magro E.
- Pastor-Galán I.
- Mata-Vázquez M.I.
- Morales M.L.
- Cuevas B.
- Vélez P.
- Martínez-Bilbao C.
- Colmenares R.
- Alonso J.M.
- Pérez-Encinas M.
- Caballero-Navarro G.
- Cortés M.Á.
- Santaliestra M.
- Raya J.M.
- Blanco-Sánchez A.
- Hernández-Rivas J.M.
- Martínez-López J.
- Ayala R.
- Álvarez-Larrán A.
Grupos
Abstract
Triple-negative essential thrombocythemia (TN-ET) represents a diagnostic and therapeutic challenge. The aim of the present study was to identify prognostic factors useful for tailoring treatment. 241 TN-ET patients with myeloid panel sequencing and confirmatory bone marrow biopsy were selected. Pathogenic/likely pathogenic variants were identified in 19.5% of patients. Mutation carriers were older (median age 66 years vs. 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616–60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43–6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk. Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001). ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001). Progression to myelofibrosis was a rare event in this cohort (2.5%). These results highlight the biological and prognostic relevance of molecular profile in TN-ET. © The Author(s) 2026.
Datos de la publicación
- ISSN/ISSNe:
- 0887-6924, 1476-5551
- Tipo:
- Article
- Páginas:
- 1968-1976
- PubMed:
- 42443413
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 4,030 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
LEUKEMIA SPRINGERNATURE
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Mutation; Prognosis; Risk Factors; Survival Rate; Thrombocythemia, Essential; adult; aged; cardiovascular disease; complication; etiology; female; genetics; heart disease risk factor; human; male; middle aged; mutation; pathology; prognosis; risk factor; survival rate; thrombocythemia; very elderly
Cita
Carreño G,Gil R,Hernández JC,Martínez JC,Bellosillo B,Pérez R,Segura A,Ferrer F,Arellano E,Angona A,García V,Noya MS,Blanco Á,Zamora L,Navarro M,Senín A,Magro E,Pastor I,Mata MI,Morales ML,Cuevas B,Vélez P,MORA E,Martínez C,Colmenares R,Alonso JM,Pérez M,Caballero G,Cortés MÁ,Santaliestra M,Raya JM,Blanco A,Hernández JM,Martínez J,Ayala R,Álvarez A. Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia. Leukemia. 2026. 40. (9):p. 1968-1976. IF:8,800. (1).
Portal de investigación